Summary of probiotic activities of Bifidobacterium lactis HN019

J Clin Gastroenterol. 2006 Oct;40(9):776-83. doi: 10.1097/01.mcg.0000225576.73385.f0.

Abstract

The bacterium, Bifidobacterium lactis HN019, has been studied for a variety of traits important to its ability to function as a probiotic. Publications documenting identity, safety, antipathogenic effects, immune enhancement, and intestinal colonization are reviewed. Most studies documenting immune effects are short term in duration (< or =6 wk feeding periods), so longer term trials would be useful to determine to what extent effects are sustained. One year-long trial feeding both galacto-oligosaccharides and HN019 in children 1 to 3 years of age provided evidence for improved growth and reduction in infection incidence. HN019 is a well-characterized probiotic strain with documented probiotic effects of meaningful magnitude especially in the area of immune system modulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bifidobacterium* / growth & development
  • Bifidobacterium* / immunology
  • Bifidobacterium* / isolation & purification
  • Dietary Supplements / microbiology
  • Gastrointestinal Diseases / immunology
  • Gastrointestinal Diseases / therapy*
  • Gastrointestinal Transit
  • Humans
  • Milk / immunology
  • Probiotics* / isolation & purification
  • Probiotics* / pharmacology
  • Probiotics* / therapeutic use